Nine Poster Presentations Include New Analyses of SILIQ® and JUBLIA®

LAVAL, Quebec, Nov. 1, 2022 – Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and its dermatology business, Ortho Dermatologics, today announced the presentation of nine posters during the Innovations in Dermatology Conference, which takes place Nov. 3-5, 2022, in Las Vegas, Nev. The presentations will feature new data around JUBLIA® (efinaconazole) Topical Solution, 10%, and SILIQ® (brodalumab) Injection, 210 mg/1.5 mL. There will also be six encore presentations, including analyses of DUOBRII® (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, ARAZLO® (tazarotene) Lotion, 0.045%, and the investigational medicine IDP-126 Gel—a combination retinoid, antibacterial and antibiotic topical.

New Educational Resource Designed to Help Support the Podiatry Community
Company Also Adds 300 Questions to Existing Dermatology Board Review Challenge

LAVAL, Quebec, Oct. 31, 2022 – Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and its dermatology business, Ortho Dermatologics, today announced the launch of the Podiatry Board Review Challenge, a new professional educational resource. Developed alongside practicing podiatrists, the Podiatry Board Review Challenge is designed to help support residents preparing for their board certification exams, podiatric healthcare professionals preparing for re-certifications and podiatrists who are looking to refresh their skills and knowledge.

Eleven Poster Presentations Include New Analyses of ARAZLO®, DUOBRII®, and IDP-126 Gel

LAVAL, Quebec, Oct. 20, 2022 – Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and its dermatology business, Ortho Dermatologics, today announced the presentation of eleven posters during the Fall Clinical Dermatology Conference, which takes place Oct. 20-23, 2022 in Las Vegas, Nev. The presentations will feature new data around ARAZLO® (tazarotene) Lotion, 0.045%, DUOBRII® (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, and the investigational medicine IDP-126 Gel—a combination retinoid, antibacterial and antibiotic topical. Two other presentations are adaptations featuring research on SILIQ® (brodalumab) Injection, 210 mg/1.5 mL. Please see below for warning about suicidal ideation and behavior with SILIQ. There will also be five encore presentations, including a systemic review of onychomycosis dermatophytoma treatment.

Scholarships Awarded to Nine Students Affected by Dermatologic Conditions

LAVAL, Quebec, Sept. 21, 2022 – Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and its dermatology business, Ortho Dermatologics, today announced the recipients of their 2022 Aspire Higher Scholarship program. The program, which has provided a total of $918,000 in scholarships since launching in 2013, will award nine students who have been treated for a dermatologic condition with a scholarship of up to $10,000 to pursue their undergraduate or graduate degrees.

Four Poster Presentations Will Include New Analyses on ARAZLO®

LAVAL, Quebec, April 27, 2022 – Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and its dermatology business, Ortho Dermatologics, today announced the presentation of four poster presentations during the Florida Society of Dermatology Physician Assistants (FSDPA) 2022 New Wave Dermatology Conference, which will take place in Coral Gables, Fla. from April 28 - May 1, 2022. The presentations will feature new clinical data on ARAZLO® (tazarotene) lotion, 0.045%, as well as several encore presentations on DUOBRII® (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, JUBLIA® (efinaconazole) Topical Solution, 10%, and SILIQ® (brodalumab) Injection. Please see below for warning about suicidal ideation and behavior with SILIQ.

Three Poster Presentations Will Include New Analyses on IDP-126 Gel, DUOBRII® and SILIQ®
Company Will Introduce New JUBLIA® Virtual Reality Experience in Booth

LAVAL, Quebec, March 22, 2022 – Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the presentation of three posters during the 2022 American Academy of Dermatology (AAD) Annual Meeting, which takes place March 25-29, 2022. The presentations will feature new analyses of the investigational medicine IDP-126 Gel and the efficacy of DUOBRII® (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, as well as results from multiple studies assessing the efficacy of SILIQ® (brodalumab) Injection for the treatment of nail and scalp psoriasis. Ortho Dermatologics will also unveil a new JUBLIA® (efinaconazole) Topical Solution, 10% virtual reality (VR) experience in the company’s booth (#917).

Students Impacted by Dermatologic Conditions Are Encouraged to Apply Through May 31, 2022

LAVAL, Quebec, March 2, 2022 – Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the opening of the application process for its 2022 Aspire Higher Scholarship program. The program, which was launched in 2013, will award nine students who have been treated for a dermatologic condition with a scholarship of up to $10,000 in support of their academic goals.

LAVAL, Quebec, Dec. 6, 2021 – Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced JUBLIA^® (efinaconazole) Topical Solution, 10%, a treatment for onychomycosis, a fungal infection of the toenails, has received the American Podiatric Medical Association (APMA) Seal of Approval. The APMA Seal of Approval is granted to products that promote good foot health and are of significant value when used in a consistently applied program of daily foot care and regular professional treatment.

Eight Poster Presentations Include New Analyses of ARAZLO®, DUOBRII® and SILIQ®

LAVAL, Quebec, Oct. 19, 2021 – Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the presentation of eight posters during the Fall Clinical Dermatology Conference, which takes place Oct. 21-24, 2021. The presentations will feature new efficacy and safety analyses of ARAZLO® (tazarotene) Lotion, 0.045%, long-term outcomes of DUOBRII® (halobetasol propionate and tazarotene) Lotion 0.01%/0.045%, quality of life improvement with SILIQ® (brodalumab) injection 210 mg/1.5 ml and new onychomycosis treatment recommendations. Please see below for warning about suicidal ideation and behavior with SILIQ. The company will also host two educational events on ARAZLO® and DUOBRII®.

Scholarships Awarded to Nine Students Affected by Dermatologic Conditions

RALEIGH, N.C., July 29, 2021 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the recipients of their 2021 Aspire Higher scholarship program. The program, which began in 2012, will award nine students who have been treated for a dermatologic condition with a scholarship up to $10,000 to pursue their undergraduate or graduate degrees.

“For nine years, Ortho Dermatologics has supported students in achieving their higher education goals through our Aspire Higher scholarship program. Beyond the demands of their schooling and extracurricular activities, these students have also had to manage the burden of living with a skin condition,” said Scott Hirsch, senior vice president and chief strategy officer, Bausch Health, and president, Ortho Dermatologics. “The stories our 2021 scholarship recipients shared with us are inspiring, and we are honored to provide them with this award to recognize their achievements and help them pursue their academic aspirations.”

All Three Co-Primary Endpoints Were Achieved

RALEIGH, N.C., April 27, 2021 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced statistically significant topline results from a second pivotal Phase 3 clinical trial evaluating its investigational medicine IDP-126, a combination retinoid, anti-bacterial and antibiotic topical, to treat acne vulgaris in patients nine years of age and older. If approved, IDP-126 would be the first-in-class with this triple combination.

Acne is the most common skin problem in the United States, affecting up to 50 million Americans.^1,2

Six Poster Presentations Include New Analyses of ARAZLO^®, DUOBRII^® and SILIQ^®

RALEIGH, N.C., April 21, 2021 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the presentation of six posters during the AAD VMX 2021, Virtual Meeting Experience, which takes place April 23-25, 2021.

One presentation will feature new analyses of ARAZLO® (tazarotene) Lotion, 0.045%, including new topline efficacy results from a post hoc analysis of Phase 3 studies on participants with moderate-to-severe acne. Approved for patients nine years or older, ARAZLO has been commercially available since 2020. Two other presentations will highlight DUOBRII® (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%. With 4 in 5 patients surveyed feeling that their current treatments are not effective enough, one of the DUOBRII posters will provide an overview of the profound effect of psoriasis on quality of life for patients, while both will include new efficacy data. The three remaining presentations will include analyses evaluating the long-term efficacy and safety profile of SILIQ® (brodalumab) Injection. Please see below for warning about suicidal ideation and behavior with SILIQ.

Students Living with Dermatologic Conditions Are Encouraged To Apply Through May 31, 2021

RALEIGH, N.C., Feb. 2, 2021 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the opening of the application process for its 2021 Aspire Higher scholarship program. The program, which began in 2013, will award nine students who have been treated for a dermatologic condition with a scholarship of up to $10,000 in support of their academic goals.

RALEIGH, N.C., Oct. 26, 2020 – Ortho Dermatologics, one of the largest dermatology health care businesses in the world, today announced the presentation of nine posters during the virtual Fall Clinical Dermatology Conference, which takes place Oct. 29 – Nov. 1, 2020. The presentations will feature new post hoc analyses on ARAZLO™ (tazarotene) Lotion, 0.045%, DUOBRII^® (halobetasol propionate and tazarotene) Lotion 0.01%/0.045%, and SILIQ^® (brodalumab) injection 210 mg/1.5 ml, as well as pediatric data on JUBLIA^® (efinaconazole) topical solution, 10%. Please see below for warning about suicidal ideation and behavior with SILIQ.

Scholarships Awarded to Nine Students Affected by Dermatologic Conditions

RALEIGH, N.C., July 27, 2020 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the recipients of their 2020 Aspire Higher scholarship program. The program, which began in 2012, will award nine students who have been treated for a dermatologic condition with a scholarship up to $10,000 to pursue their undergraduate or graduate degrees.

“At Ortho Dermatologics, we know that the physical and emotional burden of living with a skin condition can make it difficult for students to manage their academics and extracurricular activities,” said Bill Humphries, president, Ortho Dermatologics. “We are proud to continue the Aspire Higher scholarship program to help students affected by dermatologic conditions reach their educational goals, while also celebrating the positive impact dermatologists and health care professionals have had on their lives.”

ARAZLO™ (tazarotene) Lotion, 0.045% is Indicated for the Topical Treatment of Acne Vulgaris in Patients Nine Years of Age and Older

RALEIGH, N.C., June 23, 2020 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced that ARAZLO™ (tazarotene) Lotion, 0.045%, is available commercially to health care professionals starting this week. Approved by the U.S. Food and Drug Administration (FDA) in December 2019, ARAZLO is the first tazarotene acne treatment available in lotion formulation.

RALEIGH, N.C., April 29, 2020 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for JUBLIA® (efinaconazole) topical solution, 10%, a treatment for onychomycosis, a fungal infection of the toenails, which extends the age range included in the product’s label to children six years of age and older.¹ JUBLIA was first approved in June 2014 in patients 18 years and older. “Onychomycosis is increasingly being seen in pediatrics – representing 15 percent of all nail dystrophies in children,”² said Bill Humphries, president, Ortho Dermatologics. “With nearly six years of real-world use since its initial approval to treat adults in 2014, JUBLIA has a demonstrated safety and efficacy profile, and we are pleased the FDA has recognized it as a valuable treatment option for children with toenail fungal infections.”